whatshot

BMXMF   $103.5  -3.29% Market Closed

BIOMERIEUX 69 MARCY NEW
show_chart Advanced Chart of BMXMF
Last Events:

2023-03-29 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA50 changed from bearish reversal to n/a. 2021-12-01 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

2023-03-29 Trend changed from flat and down to linear down.

2023-03-29 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA50 changed from n/a to bearish reversal. 2021-12-01 the price crossed down the moving average line and demonstrates a downside trend.

2023-03-29 Trend changed from linear down to flat and down.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 90.45
Mean unverified/preliminary 90.45 / 90.45
Target Price Low / High 73.99 / 112.10
Median / STD DEV 89.68 / 9.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi Buy Sell -
macd ActivelyBuy - -
stoch Sell - -
ma20 Sell - -
ma50 Sell - -
ma100 Sell - -
ISIN FR0013280286
ceo Mr. Alexandre Merieux
Website https://www.biomerieux.com
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.